Anti-Amyloid Therapies: Progress and Promise

The FDA approval of Leqembi (lecanemab) and anticipated approval of donanemab have generated much excitement among all who are affected by Alzheimer’s disease. This roundtable highlights early experience of lecanemab at two medical centers as well as insights into the role of anti-amyloid therapies in Alzheimer’s care and how patients and families can work with their clinical team to understand their options and set realistic expectations.
Panelists:
Steven E. Arnold, MD, Harvard Medical School
David A. Wolk, MD, Penn Memory Center
Moderator: Felicia Greenfield, MSW, LCSW, Penn Memory Center
bobsmarathon.com